In an effort to help ensure its product is not removed from the marketplace by onerous requirements stipulated by regulatory agencies or by covert efforts to undermine its product quality, Longevinex® announces its proprietary red wine anti-aging capsules have passed stringent sub-acute toxicity testing, a requirement for further human testing.
Longevinex red wine capsules did not produce significant toxic side effects or mortality in laboratory mice at human equivalent doses of 3,500 and 7,000 milligrams per day (~10 to 20 oral capsules/day) in testing conducted under the supervision of Hannah R. Vasanthi, PhD, at the Department of Biotechnology, Pondicherry University, India. A complete report was published in the journal of Food & Chemical Toxicology.
As a dietary supplement, Longevinex is currently the only commercially available red wine capsule to successfully undergo toxicity testing as outlined by New Dietary Ingredient guidelines described by the Food & Drug Administration (FDA).
While toxicity testing is expensive, Longevinex will not increase its retail price to consumers. “It is just a level of assurance that consumers desire and the FDA continues to demand,” says Bill Sardi, managing partner for Longevinex.
Side-stepping efforts to make resveratrol a drug
Sardi says the FDA and the pharmaceutical industry are both overtly and covertly pushing for resveratrol to become a drug. If declared a drug, sub-acute toxicity testing would be required to keep the product available to consumers, he says.
A few thousand Americans depend upon Longevinex to maintain healthy eyes, heart, brain and blood circulation and “we don’t want any actions by regulatory agencies to restrict availability of Longevinex to needy consumers,” says Sardi.
Results of the study
There were no adverse changes in brain, heart, liver, kidney, spleen and sex organs noted after 28 days of dietary supplementation in laboratory animals. Nor were there any abnormal levels of liver enzymes, kidney toxicity or irregular blood studies such as blood sugar, cholesterol, or triglycerides. Tissue slides obtained from heart, brain, liver and kidneys showed Longevinex produced obviously healthier tissues than observed among animals given plain resveratrol or control animals given no active treatment.
In accordance with established testing methods, laboratory mice were subjected to sub-acute doses of Longevinex dietary supplement (sub-acute dosing is defined as toxicity that emanates as a result of repeated daily dosing of chemicals to experimental animals versus acute toxicity which tests for adverse effect occurring within a short time following administration such as a single dose.) Such testing is required for controlled human trials.
Efforts to undermine Longevinex science
Longevinex alleges Big Pharma is making covert efforts to classify synthetic resveratrol as a drug and to illigitimize botanically derived resveratrol from herbal sources. Longevinex is produced from Giant Knotweed, the most concentrated and abundant natural source of resveratrol.
Resveratrol researchers worldwide continue to echo the false idea that resveratrol is not biologically available (that is, makes it past the liver which detoxifies incoming molecules) when it has been clearly demonstrated that liver metabolites of resveratrol are equally effective biologically. One objective is to create bogus science to dismiss natural resveratrol and substitute patentable resveratrol-like drugs (called analogs).
Longevinex also faces more pointed opposition. Longevinex has received an unsigned letter on a major university letterhead from unidentified red wine molecule researchers which threatens that Longevinex will be put out of business if it continues in its attempts to scientifically validate its product.
“It is important for Longevinex, as the leading and best-tested brand, to validate the safety and effectiveness of its product beyond what is required for common dietary supplements and that no spurious efforts to undermine the product will be successful,” Sardi emphasizes.
An antioxidant even in mega doses
Longevinex has generated unequalled science, some never having been demonstrated in biology before.
For example, in an earlier published study, unlike plain red wine resveratrol, Longevinex was demonstrated in two species of animals, in both long and short-term tests, to exhibit no cytotoxicity (cell killing effect) at all doses tested (100 to 7000 milligrams).
Normally resveratrol is an antioxidant at low dose but undesirably promotes oxidation when given in mega doses. In animal studies, excessive-dose (more than 350 mg) resveratrol increases the area of scarring in experimentally induced heart attacks. Remarkably, Longevinex does not. It is the first time in biology this has been demonstrated.
Longevinex was shown to protect the animal heart from damage induced by an experimentally-induced heart attack about twice as well as a plain red wine pill. Evidence for this was confirmed by independent microRNA testing conducted by researchers at the National Institutes of Health.